Document Detail


Impact of on-site initiation visits on patient recruitment and data quality in a randomized trial of adjuvant chemotherapy for breast cancer.
MedLine Citation:
PMID:  17060222     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To provide empirical evidence on the impact of on-site initiation visits on the following outcomes: patient recruitment, quantity and quality of data submitted to the trial coordinating office, and patients' follow-up time. PATIENTS AND METHODS: This methodological study was performed as part of a randomized trial comparing two combination chemotherapies for adjuvant treatment of breast cancer. Centers participating to the trial were randomized to either receive systematic on-site visits (Visited group), or not (Non-visited group). RESULTS: The study was terminated after two years, while the main randomized trial continued. Of the 135 centers that had expressed an interest in the trial, only 69 randomized at least one patient (35/68 in the Visited group, 34/67 in the Non-visited group). Almost two-thirds of the patients were entered by 17 centers (10 in the Visited group, seven in the Non-visited group) that accrued more than 10 patients each. None of the prespecified outcomes favored the group of centers submitted to on-site initiation visits (ie, mean number of queries par patient: 6.1 +/- 9.7 versus 5.4 +/- 6.4, respectively for the Visited and Non-visited groups). Spontaneous transmittal of case report forms, although required by protocol, was low in both randomized groups (mean number of pages per patient: 1.5 +/- 2.0 versus 2.1 +/- 2.3, respectively), with investigators submitting about one-third of the expected forms on time (29% and 39%, respectively). LIMITATIONS: This study could not evaluate the impact of repeated on-site visits on clinical outcomes. CONCLUSION: Systematic on-site initiation visits did not contribute significantly to this clinical trial.
Authors:
J-L Liénard; E Quinaux; E Fabre-Guillevin; P Piedbois; A Jouhaud; G Decoster; M Buyse;
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical trials (London, England)     Volume:  3     ISSN:  1740-7745     ISO Abbreviation:  Clin Trials     Publication Date:  2006  
Date Detail:
Created Date:  2006-10-24     Completed Date:  2008-03-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101197451     Medline TA:  Clin Trials     Country:  England    
Other Details:
Languages:  eng     Pagination:  486-92     Citation Subset:  IM    
Affiliation:
International Drug Development Institute (IDDI), Brussels, Belgium. jean-luc.lienard@iddi.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antineoplastic Agents, Phytogenic / therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Breast Neoplasms / drug therapy*
Chemotherapy, Adjuvant
Cyclophosphamide / therapeutic use
Epirubicin / therapeutic use
Female
Fluorouracil / therapeutic use
Humans
Medical Oncology / standards*
Outcome Assessment (Health Care)*
Paclitaxel / therapeutic use
Patient Selection*
Randomized Controlled Trials as Topic / standards*
Research Design
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Phytogenic; 0/FEC protocol; 33069-62-4/Paclitaxel; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil; 56420-45-2/Epirubicin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Centralized medical monitoring in phase III clinical trials: the National Surgical Adjuvant Breast a...
Next Document:  Echelons of care and the management of wartime vascular injury: a report from the 332nd EMDG/Air For...